Epsilon Healthcare has restructured its operations, appointing Edward Jones as divisional manager of cannabis operations responsible for the company’s cannabis-producing assets THC Pharma and Canndeo.
Jones’ previous roles include leading the Valens Australia project with Cannvalate, where he assisted in the development of Valens’ presence in Australia. Prior to that he was general manager of Canopy Farms, leading the Australian operations of Canopy Growth Corporation.
He has also held positions with GMP consultancy PharmOut and biotech business CSL.
In his new role, Jones will focus on the performance of Epsilon’s Southport extraction facility, THC Pharma, where the company is looking to significantly scale up operations and pivot towards toll and contract manufacturing.
Chief executive officer Jarrod White said: “We are excited to have Edward join the Epsilon team given his experience in managing high-profile cannabis operations and his technical background in quality and project management.”
Under the restructure, the role of chief operating officer of THC Pharma, previously held by Angela Macquire, has been made redundant.
Meanwhile, Epsilon also told the ASX it has received A$1.02 million in research and development (R&T) tax incentives from the ATO for FY20.
The R&D activities during the year related to new cannabinoid extraction processes for the development of oral medicinal cannabis oils, and the company’s cannabis agronomy activities.
White said: “The receipt of these funds, combined with run-rate improvements already implemented, ensures the company is well funded to continue pursuing corporate and strategic initiatives.”
“The primary focus is revenue-generating activities including the onboarding of local and international partners seeking access to the company’s production capacity at Southport.”